HEALTH● LOWAug 10 · Aug 10, 2026, 4:59 PM
Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September
Seeking Alpha Tech
Tonix Pharmaceuticals has outlined plans for its TNX-4800 Phase II clinical trial involving approximately 3,300 participants, while also planning to scale its TONMYA sales force to about 150 representatives by September. This indicates key operational and research developments for the company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoDiphtheria: Data Shows About 68% Of Confirmed Cases Are Unvaccinated — NCDCChannels TVHEALTH2h agoDoctors question the need to register again for National Medical RegisterThe HinduHEALTH2h agoSeptember Out of the Darkness walks raise money , support for suicide awareness and preventioncandgnews.com · United StatesHEALTH2h agoPT Health Watch: Common cancer risk factors that should not be ignoredPremium Times